8-K: Elanco Animal Health Reports First Quarter 2025 Results, Raises Full Year Revenue Guidance

Elanco Animal Health reports a mixed Q1 2025 with a slight revenue dip but raises full-year revenue guidance driven by foreign exchange tailwinds and strong performance.

Summary

• Elanco Animal Health reported its first quarter 2025 financial results on May 7, 2025.
• Revenue for Q1 2025 was $1,193 million, a 1% decrease year-over-year, but showed 4% organic constant currency growth.
• Reported net income was $67 million, with an adjusted net income of $184 million.
• Adjusted EBITDA was $276 million, representing 23.1% of revenue.
• Reported EPS was $0.13, while adjusted EPS was $0.37.
• The company is raising its full-year 2025 revenue guidance to $4,510 to $4,580 million, an increase of $65 to $70 million since February, driven by foreign exchange tailwinds.
• Elanco is also raising its 2025 innovation revenue target to $660 to $740 million.
• The company expects a gross debt paydown of $450 to $500 million in 2025.
• Elanco improved its year-end net leverage ratio target to 3.9x to 4.3x.
• Second quarter 2025 revenue is expected to be $1,175 to $1,195 million.
• The company expects full year adjusted EBITDA of $830 to $870 million.
• The company expects full year adjusted EPS of $0.80 to $0.86.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to raised revenue guidance and strong performance in certain areas, offset by some revenue decline and macroeconomic uncertainties.

Positives

• Elanco exceeded first quarter guidance for revenue, adjusted EBITDA, and adjusted EPS.
• The company's diverse portfolio delivered 4% organic constant currency revenue growth.
• Pet Health trends are accelerating.
• Farm Animal execution is consistently strong.
• The company is driving greater productivity and deleveraging.
• The net leverage target for year-end has been improved.
• Credelio Quattro achieved approximately 10% dollar share of broad-spectrum sales into U.S. vet clinics in Q1.
• Zenrelia use is in approximately 11,000 U.S. clinics, representing penetration of over 35%.

Negatives

• First quarter revenue decreased by 1% year-over-year on a reported basis.
• Adjusted EBITDA decreased by 6% compared to the first quarter of 2024.
• Cash used in operations was $4 million in the first quarter of 2025 compared to cash provided by operations of $2 million in the first quarter of 2024.
• The company expects a headwind to revenue of approximately $5 million from the unfavorable impact of foreign exchange rates compared to prior year in the second quarter.

Risks

• The company acknowledges a dynamic macroeconomic backdrop and takes a prudent approach to the balance of the year.
• The outlook incorporates a current estimate for tariff net impact of $16 to $20 million to Adjusted EBITDA.
• The company expects continued macro volatility.
• The company expects operating expenses up approximately 11% year over year in constant currency with strategic investment in the global launches of the innovation portfolio.

Future Outlook

Elanco expects revenue growth to accelerate to mid-single digits, excluding the impact of foreign exchange rates and the aqua divestiture, and anticipates a year-end net leverage ratio of 3.9x to 4.3x. The company is strategically investing in the global launches of its innovation portfolio.

Management Comments

• Elanco exceeded first quarter guidance for revenue, adjusted EBITDA, and adjusted EPS, said Jeff Simmons, President and CEO of Elanco.
• We have raised our 2025 revenue guidance given the FX tailwind, and we have increased our innovation revenue target, led by the commercialization of our potential blockbuster products which also enhance our stable base business, said Jeff Simmons, President and CEO of Elanco.
• We are also accelerating our debt paydown to approximately half a billion dollars this year, now expecting to end 2025 with a net leverage ratio of 3.9x to 4.3x, said Todd Young, Executive Vice President and CFO of Elanco Animal Health.

Industry Context

Elanco operates in the competitive animal health industry, facing competition from various players offering similar products and services. The company's focus on innovation and strategic acquisitions aims to maintain its market position and drive growth.

Comparison to Industry Standards

• Zoetis, a major player in the animal health industry, reported Q1 2024 revenue of $2.2 billion, showcasing the scale of larger competitors.
• Merck Animal Health reported Q1 2024 sales of $1.5 billion, indicating the competitive landscape Elanco operates within.
• Elanco's focus on debt reduction aligns with industry trends towards financial discipline and efficient capital allocation.

Stakeholder Impact

• Shareholders can expect increased value through revenue growth and debt reduction.
• Customers will benefit from innovative products and services.
• Employees may see increased opportunities due to company growth.

Next Steps

• Elanco will host a webcast and conference call to review first quarter financial and operational results, discuss second quarter and full year 2025 financial guidance, and respond to questions from analysts.

Key Dates

Keywords

Elanco, Animal Health, Financial Results, Guidance, Revenue, EBITDA, EPS, Debt Paydown, Pet Health, Farm Animal